Market Overview

Rewalk's Robotic Stroke Therapy System Gets FDA Nod, Shares Soar 175%

Share:
Rewalk's Robotic Stroke Therapy System Gets FDA Nod, Shares Soar 175%

Shares of nanocap medical device company Rewalk Robotics Ltd (NASDAQ: RWLK) soared in pre-market trading Wednesday.

What Happened

Israel-based Rewalk said the FDA has cleared its ReStore soft exo-suit system for sale to rehabilitation centers across the United States.

The maker of robotic medical devices for individuals with lower limb disabilities said Restore is the only soft exo-suit approved by the FDA and is intended to treat stroke survivors with mobility challenges.

The system has a launch price of $28,900, as well as leasing options.

Why It's Important

Stroke is the leading cause of disability affecting about 17 million people worldwide each year, with about 80 percent of the people who have had a stroke suffering from gait impairments, Rewalk said.

"The exo-suit achieves our commercial goal to offer a functional and affordable system that can be utilized in the 'Main Street' clinics in every community," said ReWalk CEO Larry Jasinski.

Rewalk expects to publish the results of a multi-center clinical study of the ReStore system conducted across five of its leading rehabilitation later this year.

At time of publication, Realk's stock was trading higher by 175 percent to $5.81 per share. The stock previously closed at $3.32.

Related Links:

Obalon Clinches First US Patent For Obesity Treatment Placement System

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Posted-In: News FDA Top Stories Movers Trading Ideas Best of Benzinga

 

Related Articles (RWLK)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Gamers Rejoice: You've Got Another ETF

The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache